Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (abre uma nova janela)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indexado‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (abre uma nova janela)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (abre uma nova janela)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Fonte‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indexado‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (abre uma nova janela)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (abre uma nova janela)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indexado‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (abre uma nova janela)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (abre uma nova janela)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Fonte‎: Blood 2003;102(4):1529-30.

Indexado‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (abre uma nova janela)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (abre uma nova janela)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Fonte‎: Transfusion 2007;47(10):1830-6.

Indexado‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (abre uma nova janela)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (abre uma nova janela)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Fonte‎: Iran J Blood Cancer 2009;1(4):147-50.

Indexado‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (abre uma nova janela)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (abre uma nova janela)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Fonte‎: Int J Hematol 2012;95(1):51-6.

Indexado‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (abre uma nova janela)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (abre uma nova janela)

Perrine SP.

Fonte‎: Pediatr Ann 2008;37(5):339-46.

Indexado‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (abre uma nova janela)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (abre uma nova janela)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Fonte‎: Sci Rep. 2022;12(1):2752.

Indexado‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (abre uma nova janela)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (abre uma nova janela)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Fonte‎: Haematologica 2004;89(10):1172-8.

Indexado‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (abre uma nova janela)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (abre uma nova janela)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Fonte‎: Arch Iran Med 2009;12(3):295-7.

Indexado‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (abre uma nova janela)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (abre uma nova janela)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Fonte‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indexado‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (abre uma nova janela)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (abre uma nova janela)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Fonte‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indexado‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (abre uma nova janela)

Fetal globin gene inducers: novel agents and new potential. (abre uma nova janela)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Fonte‎: Ann N Y Acad Sci 2010;1202:158-64.

Indexado‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (abre uma nova janela)